美国东部时间2023年4月29日）由波士顿华人投资协会（BCIC）牵头主办的第二届国际生物医疗创投大赛在美国波士顿成功落幕。“BCIC国际生物医疗创投大赛”以挖掘优质的早期生物医疗项目为核心，为初创公司和投资方之间的有效对接创造交流的平台，进而加速科技成果的全球化商业转化。
回顾去年的大赛，先后有48支项目团队报名参赛6支项目团队进入决赛，其中三家公司Amytrx Therapeutics, ARIZ Precision Medicine, Biostage在随后的一年中分别成功融资二百万美元到一千八百万美元。而Xsmart团队已经在国内落地并开始盈利。由协会经过多年孵化的项目BosEagle Surgical Inc也获得了香港科技园的落地资助。
今年的创赛竞争空前激烈，共有来自全球86家生物医疗创业公司（其中五个公司有多位美国院士），经过历时半年的数轮角逐后18支团队闯进总决赛。
本次决赛赞助奖项和获奖数额也都突破了历史水准，BCIC特公布获奖名单如下并向各位获奖的团队致以热烈的祝贺：
第一名：
Myro Therapeutics 通过研究神经中枢疾病机制，研发一流的神经再生小分子疗法。
第二名：
InGel Therapeutics INC 哈佛的衍生公司，为因视网膜退化而丧失视力的患者开发基于细胞的疗法。他们的抢滩适应症是色素性视网膜炎，未来会扩展到干性年龄相关性黄斑变性和青光眼。
第二名：
Full Circles Therapeutics Full Circles 通过敲入/敲出非病毒基因编写平台创新基因组工程解决方案，该平台能够发现、开发和制造新型治疗性基因组药物。
第三名：
Neodroid Biosciences Neodroid 是一家开发下一代纳米医学的初创公司。为了应对关键的生物制药挑战，公司开发了用于增强癌症免疫疗法的 PromoRNA；用于器官定义疾病的 PromoDNA；CytoDirect 用于细胞特异性直接递送至细胞质；和用于多价、多功能靶向的 Synbody
第三名：
Elpis Biopharmaceuticals Elpis 是一家位于波士顿的临床阶段生物技术公司。Elpis 正在开发多模块同种异体 gamma/delta CAR-T 和 CAR-NK 疗法，旨在为治疗实体瘤和其他类型的癌症提供持久的抗肿瘤活性。
第三名：
DoriVac DoriVac 是一家临床前生物技术初创公司，使用 DNA 纳米技术开发癌症免疫疗法。DoriVac 提供个性化癌症疫苗平台，利用 DNA 折纸技术以纳米级精度控制共呈递肿瘤抗原和佐剂配体的间距和几何形状。
2支获得创新奖的团队是：
Dart Biosciences，Likarda, LLC，FuseBio， CartaBio，Aplife Biotech，Adcura, Inc，SunVax mRNA Therapeutics, Inc.， Great Bay Bio， Santolecan Pharmaceuticals LLC，Elpis Biopharmaceuticals, Cellula BioPharma, Inc.， 511 Therapeutics Inc.
致谢：
本次比赛离不开上海张江科技园、香港科技园、美国JJLake、美迪西、朴道资本、欣谷创服、维亚生物、ATLATL、巢生创新实验室、AAEA、旅美科协波士顿、无名资本、行远致同、AMFA、外联、安永、Q Bay，HiCool等鼎力合办，协助，和赞助，以及长期支持我们的易方达基金以及Vacovec, Mayotte & Singer，海投和Dolphin Capital。同时，感谢所有合作伙伴和全程直播的E药经理人、深蓝观、赛柏蓝、以及HiCool。本次直播共计上万人在线观看。最后感谢波士顿华人投资协会的全体工作人员和志愿者几个月以来的辛苦筹备和付出。也感谢和祝福协会新衍生出来的生物医疗投资和服务公司 AlphaBio Ventures LLC（后续会有介绍）。
On April 29th，Boston Chinese Investment Club (BCIC) successfully held the 2nd international biotech start-up pitch competition. Since the beginning of 2023, the international biotech start-up pitch competition sponsored by BCIC has gradually unfolded. The purpose of the competition is to explore early-stage biotech projects with high quality and potential in North America and other regions, to accelerate the transfer and transformation of scientific and technological achievements, and to promote effective communication between startups and investors.
In this competition, excellent teams from 86 biotech-related startups from around the world participated. After several exciting rounds of competition, a total of 16 teams made it to the final. Let us first congratulate the winning teams:
First place: Myro Therapeutics develops first-class small molecule therapies by studying the mechanisms of central nervous system diseases.
Second place: InGel Therapeutics INC, a Harvard spin-off company, develops cell-based therapies for patients who have lost their vision due to retinal degeneration. Their initial target indication is pigmentary retinopathy, with plans to expand to dry age-related macular degeneration and glaucoma.
Second place: Full Circles Therapeutics uses an innovative genome engineering solution with a knock-in/knock-out non-viral gene writing platform to discover, develop, and manufacture new therapeutic genome drugs.
Third place: Neodroid Biosciences is a startup company developing next-generation nanomedicine. To address key biopharmaceutical challenges, they have developed PromoRNA for enhancing cancer immunotherapy; PromoDNA for organ-defined diseases; CytoDirect for cell-specific direct delivery to the cytosol; and Synbody for multi-valent, multi-functional targeting.
Third place: Elpis Biopharmaceuticals is a clinical-stage biotech company based in Boston. Elpis is developing multi-module homologous gamma/delta CAR-T and CAR-NK therapies to provide durable anti-tumor activity for the treatment of solid tumors and other types of cancer.
Third place: DoriVac is a preclinical biotech startup that develops cancer immunotherapy using DNA nanotechnology. DoriVac offers a personalized cancer vaccine platform that uses DNA origami technology to control the spacing and geometry of co-presented tumor antigens and adjuvant ligands with nanometer precision.
Innovation award winners: Dart Biosciences, Likarda, LLC, FuseBio, CartaBio, Aplife Biotech, Adcura, Inc, SunVax mRNA Therapeutics, Inc., Great Bay Bio, Santolecan Pharmaceuticals LLC, Elpis Biopharmaceuticals, Cellula BioPharma, Inc. , 511 Therapeutics Inc.
This competition would not have been possible without the strong support and sponsorship from Shanghai Zhangjiang Science City, Hong Kong Science and Technology Park, Suzhou Jinji Lake Science and Technology Park, Medisun, Pudao Capital, Xingu Chuangfu, Viya Biomedical, ATLATL, Chaosheng Innovation Laboratory, AAEA, Boston Chinese Investment Club (BCIC), Wuming Capital, Xing Yuan Zhi Tong, AMFA, WELINK, EY, and QBay, as well as the long-term support from our sponsor, E Fund Management Co., Ltd. We also thank all our partners and the live stream supporters, E Pharm Manager, Shenlan Guan, CyberBlue, Hicool, and the thousands of online viewers. Special thanks to Ms. Wang Chen, founder of Shenlan Guan, for her Chinese translation and publicity efforts, which helped more people to learn about our event. We would also like to thank all the staff and volunteers of BCIC for their hard work and contributions in organizing this event over the past few months. Your efforts have been key to our success.
We welcome all organizations to support, sponsor, and collaborate with us. BCIC, formerly known as the Boston Chapter of the Chinese Finance Association of North America, is committed to promoting exchanges and discussions in Chinese finance and investment, building a platform for connecting Chinese and American capital and projects, providing investment opportunities, professional and social services to our members, and actively contributing to the talent and advice of China’s investment and financial industry. We have branches and offices in New York, Washington, Beijing, Shanghai, Chengdu, and Shenzhen, with over 6,000 members widely distributed around the world.
Through this competition, we have seen excellent projects and entrepreneurial teams from all over the world and have built a platform for exchanges and cooperation in the field of biomedicine entrepreneurship. Secondly, this competition has injected new vitality and impetus into the innovation and development of the biomedicine industry, and is expected to promote the rapid development and transformation of the industry. Finally, this competition has also promoted international exchanges and cooperation, making positive contributions to the common prosperity and development of the global biomedicine industry. We believe that in the future, the impact of this competition will continue to expand and extend, injecting continuous energy and vitality into the long-term development and prosperity of the biomedicine industry. A for-profit entity AlphaBio Ventures LLC was set up to facilitate global outstanding healthcare startups in funding raising and expanding across USA and Asia market.
全体获奖团队和评委以及合办方们合影
协会和杰出嘉宾哈佛医学院Wagner教授院士合影
协会组织者团队合影
AlphaBio Ventures LLC 部分成员
【BCIC Sponsors】
E Fund Management Co., LTD.
U.S. & International Tax and Legal Services
Shanghai Zhangjiang Boston Enterprise Park
(http://www.zjbostonpark.com/)
Global Asset Management
(https://www.haitouglobal.com/)
Dolphin Capital
JJLake Asian Future Innovation Challenge Boston Chapter
Hong Kong Science Technology Park
(https://bcicglobal.org/sponsors/)
Start Point Advisors/行远致同
Financial Advisors for Healthcare Startups
Early stage capital for startups in Healthcare and Consumption
Boston Chinese Investment Club (BCIC) is a non-profit organization founded in 2010 with more 6000 professionals in Finance, Venture Capital, and various technology industries. It serves as a Boston centered platform for exchanging ideas, knowledge, and information in finance and related areas between US and China. Main activities include summits, conferences, and seminars. （https://bcicglobal.org/）
